ZA200605587B - Novel phenylalanine derivative - Google Patents

Novel phenylalanine derivative Download PDF

Info

Publication number: ZA200605587B
Authority: ZA; South Africa
Prior art keywords: group; pharmaceutically acceptable; acceptable salts; carbon atoms; hydrogen atom
Prior art date: 2003-12-22

Application number

ZA200605587A

Other languages

English (en)

Inventor

Sagi Kazuyuki

Okuzumi Tatsuya

Yamada Tatsuhiro

Shunsuke Kageyama

Yoichiro Shima

Nakagawa Tadakiyo

Tokumasu Munetaka

Masayuki Sugiki

Ito Hajime

Tanabe Itsuya

Suzuki Tamotsu

Nakayama Akira

Ubukata Kazuyuki

Shinkai Kenji

Tanaka Yasuhiro

Noguchi Misato

Andou Ayatoshi

Yamamoto Yoriko

Kataoka Noriyasu

Koichi Fujita

Original Assignee

Ajinomoto Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-22

Filing date

2004-12-22

Publication date

2008-02-27

2004-12-22 Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk

2008-02-27 Publication of ZA200605587B publication Critical patent/ZA200605587B/en

Links

150000002993 phenylalanine derivatives Chemical class 0.000 title claims description 85
-1 morpholinoethyloxy group Chemical group 0.000 claims description 128
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 115
125000004432 carbon atom Chemical group C* 0.000 claims description 94
239000000460 chlorine Substances 0.000 claims description 92
150000003839 salts Chemical class 0.000 claims description 85
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
229910052731 fluorine Inorganic materials 0.000 claims description 60
229910052801 chlorine Inorganic materials 0.000 claims description 55
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 52
125000003545 alkoxy group Chemical group 0.000 claims description 49
125000000217 alkyl group Chemical group 0.000 claims description 47
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 45
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 34
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 27
SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical group C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 15
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 13
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 13
229940124597 therapeutic agent Drugs 0.000 claims description 13
230000003449 preventive effect Effects 0.000 claims description 12
125000001153 fluoro group Chemical group F* 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 10
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 10
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
208000026935 allergic disease Diseases 0.000 claims description 7
230000007170 pathology Effects 0.000 claims description 7
206010020751 Hypersensitivity Diseases 0.000 claims description 6
206010027476 Metastases Diseases 0.000 claims description 6
230000007815 allergy Effects 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 6
206010012601 diabetes mellitus Diseases 0.000 claims description 6
230000009401 metastasis Effects 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 5
208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
125000001309 chloro group Chemical group Cl* 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
208000037803 restenosis Diseases 0.000 claims description 5
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
229940123038 Integrin antagonist Drugs 0.000 claims description 4
208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
230000035755 proliferation Effects 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 3
101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
125000003386 piperidinyl group Chemical group 0.000 claims description 3
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
206010003246 arthritis Diseases 0.000 claims description 2
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims 2
QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 claims 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
241000272522 Anas Species 0.000 claims 1
241001442234 Cosa Species 0.000 claims 1
101000851593 Homo sapiens Separin Proteins 0.000 claims 1
241000532353 Porzana Species 0.000 claims 1
241000568452 Sania Species 0.000 claims 1
102100036750 Separin Human genes 0.000 claims 1
230000005021 gait Effects 0.000 claims 1
108010044426 integrins Proteins 0.000 description 24
102000006495 integrins Human genes 0.000 description 24
108010008212 Integrin alpha4beta1 Proteins 0.000 description 20
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 20
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 20
210000004027 cell Anatomy 0.000 description 17
150000001875 compounds Chemical class 0.000 description 15
201000010099 disease Diseases 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
210000000265 leukocyte Anatomy 0.000 description 10
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
230000010062 adhesion mechanism Effects 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
230000003042 antagnostic effect Effects 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
108010067306 Fibronectins Proteins 0.000 description 6
102000016359 Fibronectins Human genes 0.000 description 6
206010046851 Uveitis Diseases 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
210000003989 endothelium vascular Anatomy 0.000 description 6
239000003446 ligand Substances 0.000 description 6
206010002556 Ankylosing Spondylitis Diseases 0.000 description 5
206010009900 Colitis ulcerative Diseases 0.000 description 5
208000011231 Crohn disease Diseases 0.000 description 5
201000006704 Ulcerative Colitis Diseases 0.000 description 5
208000026106 cerebrovascular disease Diseases 0.000 description 5
102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 4
101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 4
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 4
208000006454 hepatitis Diseases 0.000 description 4
125000005553 heteroaryloxy group Chemical group 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
210000001986 peyer's patch Anatomy 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
206010003827 Autoimmune hepatitis Diseases 0.000 description 3
206010008609 Cholangitis sclerosing Diseases 0.000 description 3
206010008909 Chronic Hepatitis Diseases 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
206010015084 Episcleritis Diseases 0.000 description 3
206010015226 Erythema nodosum Diseases 0.000 description 3
208000007465 Giant cell arteritis Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
201000001263 Psoriatic Arthritis Diseases 0.000 description 3
206010039705 Scleritis Diseases 0.000 description 3
201000009594 Systemic Scleroderma Diseases 0.000 description 3
206010042953 Systemic sclerosis Diseases 0.000 description 3
208000030886 Traumatic Brain injury Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
206010008118 cerebral infarction Diseases 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
201000004614 iritis Diseases 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
201000010260 leiomyoma Diseases 0.000 description 3
210000003563 lymphoid tissue Anatomy 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
229960005190 phenylalanine Drugs 0.000 description 3
235000008729 phenylalanine Nutrition 0.000 description 3
201000011461 pre-eclampsia Diseases 0.000 description 3
201000000742 primary sclerosing cholangitis Diseases 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
208000010157 sclerosing cholangitis Diseases 0.000 description 3
208000020431 spinal cord injury Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
206010043207 temporal arteritis Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000009529 traumatic brain injury Effects 0.000 description 3
101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101710178046 Chorismate synthase 1 Proteins 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
101710152695 Cysteine synthase 1 Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
102100032831 Protein ITPRID2 Human genes 0.000 description 2
206010039361 Sacroiliitis Diseases 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
125000002102 aryl alkyloxo group Chemical group 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
101150113676 chr1 gene Proteins 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
208000009954 pyoderma gangrenosum Diseases 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
101100495912 Arabidopsis thaliana CHR12 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
235000011960 Brassica ruvo Nutrition 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102100023471 E-selectin Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
102100025323 Integrin alpha-1 Human genes 0.000 description 1
102100032816 Integrin alpha-6 Human genes 0.000 description 1
108010041341 Integrin alpha1 Proteins 0.000 description 1
108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
108010041100 Integrin alpha6 Proteins 0.000 description 1
108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000007000 Tenascin Human genes 0.000 description 1
108010008125 Tenascin Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
125000004410 cyclooctyloxy group Chemical group C1(CCCCCCC1)O* 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000000264 venule Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200605587A 2003-12-22 2004-12-22 Novel phenylalanine derivative ZA200605587B (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2003425347		2003-12-22
JP2004074943		2004-03-16
JP2004159919		2004-05-28
JP2004260319		2004-09-07

Publications (1)

Publication Number	Publication Date
ZA200605587B true ZA200605587B (en)	2008-02-27

Family

ID=34714482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200605587A ZA200605587B (en)	2003-12-22	2004-12-22	Novel phenylalanine derivative

Country Status (15)

Country	Link
US (2)	US7345049B2 (ru)
EP (3)	EP2615087A3 (ru)
JP (1)	JP4743659B2 (ru)
KR (2)	KR101194176B1 (ru)
CN (2)	CN103784458B (ru)
AU (1)	AU2004303696B2 (ru)
BR (1)	BRPI0418026A (ru)
CA (1)	CA2550843C (ru)
ES (1)	ES2548853T3 (ru)
IL (1)	IL176469A (ru)
NO (1)	NO337628B1 (ru)
NZ (1)	NZ548420A (ru)
RU (1)	RU2390520C2 (ru)
WO (1)	WO2005061466A1 (ru)
ZA (1)	ZA200605587B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7874001A (en)	2000-08-18	2002-03-04	Ajinomoto Kk	Novel phenylalanine derivatives
DE60124573T2 (de) *	2000-09-29	2007-06-21	Ajinomoto Co., Inc.	Neue phenylalanin-derivate
AU2003211560A1 (en) *	2002-02-20	2003-09-09	Ajinomoto Co., Inc.	Novel phenylalanine derivative
CN100436429C (zh) *	2003-02-20	2008-11-26	味之素株式会社	具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
WO2005046696A1 (ja) *	2003-11-14	2005-05-26	Ajinomoto Co., Inc.	フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
JP4947482B2 (ja) *	2003-11-14	2012-06-06	味の素株式会社	フェニルアラニン誘導体の徐放性経口投与製剤
WO2005051925A1 (ja) *	2003-11-27	2005-06-09	Ajinomoto Co., Inc.	フェニルアラニン誘導体の結晶及びその製造方法
EP2615087A3 (en) *	2003-12-22	2013-08-07	Ajinomoto Co., Inc.	Phenylalanine derivatives
JP5046188B2 (ja) *	2005-06-21	2012-10-10	味の素株式会社	フェニルアラニン誘導体の結晶、その製造方法及びその使用
WO2007028789A1 (en) *	2005-09-07	2007-03-15	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Quinazoline derivatives as antiviral agents
WO2007060409A1 (en) *	2005-11-23	2007-05-31	Astrazeneca Ab	L-alanine derivatives
CA2635531C (en)	2005-12-29	2014-06-17	Lexicon Pharmaceutical Inc.	Multicyclic amino acid derivatives and methods of their use
US7834050B2 (en) *	2006-03-29	2010-11-16	Duke University	Small molecule insulin mimetics absent quinones
WO2007141473A1 (en) *	2006-06-09	2007-12-13	Astrazeneca Ab	N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
ES2380135T3 (es)	2006-11-22	2012-05-08	Ajinomoto Co., Inc.	MÃ©todo de preparaciÃ³n de derivados de fenilalanina que tienen esqueleto de quinazolinadiona e intermedios para su preparaciÃ³n
WO2008093065A1 (en) *	2007-01-29	2008-08-07	Astrazeneca Ab	L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) *	2007-04-11	2008-10-23	Astrazeneca Ab	N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US20100113391A1 (en) *	2007-04-19	2010-05-06	Astellas Pharma Inc.	Bicyclic heterocyclic compound
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011122619A1 (ja)	2010-03-29	2011-10-06	味の素株式会社	フェニルアラニン誘導体の塩の結晶
US8501982B2 (en)	2010-06-09	2013-08-06	Receptos, Inc.	GLP-1 receptor stabilizers and modulators
DK2713722T3 (en)	2011-05-31	2017-07-03	Celgene Int Ii Sarl	Newly known GLP-1 receptor stabilizers and modulators
RU2634896C2 (ru) *	2011-12-12	2017-11-08	Селджин Интернэшнл Ii Сарл	Новые модуляторы рецептора glp-1
DK2842945T3 (en)	2012-04-24	2017-01-30	Ea Pharma Co Ltd	Sulfonamide derivative and medical use thereof
CN102993105B (zh) *	2012-12-19	2014-06-11	西南大学	1-甲基-2,4-喹唑啉二酮衍生物及其制备方法和应用
ES2864349T3 (es) *	2013-06-11	2021-10-13	Receptos Llc	Nuevos moduladores del receptor GLP-1
ES2778200T3 (es)	2013-10-29	2020-08-10	Ea Pharma Co Ltd	Derivado de sulfonamida y su uso medicinal
KR102564946B1 (ko)	2014-07-25	2023-08-08	리셉토스 엘엘씨	신규 glp-1 수용체 조절제
CA2969944A1 (en) *	2014-12-10	2016-06-16	Celgene International Ii Sarl	Glp-1 receptor modulators
JP2018535958A (ja)	2015-10-27	2018-12-06	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
AU2017214589B2 (en)	2016-02-05	2020-09-03	Ea Pharma Co., Ltd.	Sulfonamide derivative and pharmaceutical composition containing same
AU2019373240B2 (en)	2018-10-30	2023-04-20	Gilead Sciences, Inc.	Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en)	2018-10-30	2023-07-13	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
CN112969504B (zh)	2018-10-30	2024-04-09	吉利德科学公司	用于抑制α4β7整合素的化合物
KR102641718B1 (ko)	2018-10-30	2024-02-29	길리애드 사이언시즈, 인코포레이티드	알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2021030438A1 (en)	2019-08-14	2021-02-18	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4111394A1 (de)	1991-04-09	1992-10-15	Behringwerke Ag	Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
DK0626861T4 (da)	1992-01-13	2004-08-16	Biogen Inc	Behandling af astma.
ATE151642T1 (de)	1992-02-12	1997-05-15	Biogen Inc	Behandlung für entzündungserkrankung des darmes
EP0677060A1 (en)	1993-01-08	1995-10-18	Tanabe Seiyaku Co., Ltd.	Peptide inhibitors of cell adhesion
DE69419721T2 (de)	1993-01-12	2000-04-27	Biogen Inc	Rekombinante anti-vla4 antikörpermoleküle
WO1995015973A1 (en)	1993-12-06	1995-06-15	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
EP0804237B8 (en)	1994-01-25	2006-11-08	Elan Pharmaceuticals, Inc.	Humanized antibodies against leukocyte adhesion molecule vla-4
AU2958195A (en)	1994-06-29	1996-01-25	Texas Biotechnology Corporation	Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
DE19650975A1 (de) *	1996-12-09	1998-06-10	Basf Ag	Neue heterocyclisch substituierte Benzamide und deren Anwendung
CA2282277C (en)	1997-02-28	2005-10-11	Pfizer Products Inc.	Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
CN1133648C (zh)	1997-07-31	2004-01-07	伊兰药品公司	抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
PT1005446E (pt)	1997-08-22	2004-06-30	Hoffmann La Roche	Derivados de n-aroilfenilalanina
DK1005445T3 (da)	1997-08-22	2004-10-04	Hoffmann La Roche	N-alkanoylphenylaninderivater
US6197794B1 (en)	1998-01-08	2001-03-06	Celltech Therapeutics Limited	Phenylalanine derivatives
MY153569A (en)	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
DE69919334T2 (de)	1998-02-26	2005-08-04	Celltech Therapeutics Ltd., Slough	Phenylalaninderivate als inhibitoren von alpha4 integrinen
DE19817461A1 (de) *	1998-04-20	1999-10-21	Basf Ag	Neue substituierte Benzamide, deren Herstellung und Anwendung
DE19818614A1 (de) *	1998-04-20	1999-10-21	Basf Ag	Neue substituierte Amide, deren Herstellung und Anwendung
US6171578B1 (en) *	1999-04-14	2001-01-09	Diatide, Inc.	Benzodiazepine derivatives for imaging thrombi
JP3795305B2 (ja)	1999-07-19	2006-07-12	田辺製薬株式会社	医薬組成物
GB2354440A (en)	1999-07-20	2001-03-28	Merck & Co Inc	Aryl amides as cell adhesion inhibitors
JP4788939B2 (ja)	1999-11-18	2011-10-05	味の素株式会社	新規フェニルアラニン誘導体
ATE357433T1 (de)	1999-12-06	2007-04-15	Hoffmann La Roche	4-pyrimidinyl-n-acyl-l-phenylanine
NZ518888A (en)	1999-12-06	2004-02-27	F	4-pyridinyl-N-acyl-L-phenylalanines
JP4784803B2 (ja)	1999-12-28	2011-10-05	味の素株式会社	新規フェニルアラニン誘導体
AU2001242743A1 (en)	2000-03-23	2001-10-03	Ajinomoto Co. Inc.	Novel phenylalanine derivative
US6960597B2 (en)	2000-06-30	2005-11-01	Orth-Mcneil Pharmaceutical, Inc.	Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU7874001A (en) *	2000-08-18	2002-03-04	Ajinomoto Kk	Novel phenylalanine derivatives
MY129000A (en)	2000-08-31	2007-03-30	Tanabe Seiyaku Co	INHIBITORS OF a4 MEDIATED CELL ADHESION
DE60124573T2 (de)	2000-09-29	2007-06-21	Ajinomoto Co., Inc.	Neue phenylalanin-derivate
JP4164871B2 (ja)	2001-07-26	2008-10-15	味の素株式会社	新規フェニルプロピオン酸誘導体
EP1454898A4 (en)	2001-12-13	2006-12-13	Ajinomoto Kk	NEW PHENYL ALANIDE DERIVATIVES
AU2003211560A1 (en)	2002-02-20	2003-09-09	Ajinomoto Co., Inc.	Novel phenylalanine derivative
CN100436429C (zh)	2003-02-20	2008-11-26	味之素株式会社	具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
KR20060113700A (ko) *	2003-10-03	2006-11-02	포톨라 파마슈티컬스, 인코포레이티드	2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아
WO2005051925A1 (ja)	2003-11-27	2005-06-09	Ajinomoto Co., Inc.	フェニルアラニン誘導体の結晶及びその製造方法
EP2615087A3 (en)	2003-12-22	2013-08-07	Ajinomoto Co., Inc.	Phenylalanine derivatives
ES2380135T3 (es) *	2006-11-22	2012-05-08	Ajinomoto Co., Inc.	MÃ©todo de preparaciÃ³n de derivados de fenilalanina que tienen esqueleto de quinazolinadiona e intermedios para su preparaciÃ³n

2004
- 2004-12-22 EP EP13152904.2A patent/EP2615087A3/en not_active Withdrawn
- 2004-12-22 ES ES04808055.0T patent/ES2548853T3/es active Active
- 2004-12-22 ZA ZA200605587A patent/ZA200605587B/en unknown
- 2004-12-22 CN CN201410016206.3A patent/CN103784458B/zh not_active Expired - Fee Related
- 2004-12-22 EP EP14181015.0A patent/EP2803667A1/en not_active Withdrawn
- 2004-12-22 RU RU2006126651/04A patent/RU2390520C2/ru not_active IP Right Cessation
- 2004-12-22 KR KR1020067014754A patent/KR101194176B1/ko active IP Right Grant
- 2004-12-22 KR KR1020117019338A patent/KR20110098980A/ko not_active Application Discontinuation
- 2004-12-22 WO PCT/JP2004/019704 patent/WO2005061466A1/ja active Application Filing
- 2004-12-22 CN CN200480041967.9A patent/CN1917881B/zh not_active Expired - Fee Related
- 2004-12-22 CA CA2550843A patent/CA2550843C/en not_active Expired - Fee Related
- 2004-12-22 JP JP2005516537A patent/JP4743659B2/ja not_active Expired - Fee Related
- 2004-12-22 EP EP04808055.0A patent/EP1700850B1/en active Active
- 2004-12-22 AU AU2004303696A patent/AU2004303696B2/en not_active Ceased
- 2004-12-22 NZ NZ548420A patent/NZ548420A/en not_active IP Right Cessation
- 2004-12-22 BR BRPI0418026-7A patent/BRPI0418026A/pt not_active IP Right Cessation
- 2004-12-22 US US11/018,226 patent/US7345049B2/en not_active Expired - Fee Related
2006
- 2006-06-21 IL IL176469A patent/IL176469A/en active IP Right Grant
- 2006-07-20 NO NO20063372A patent/NO337628B1/no not_active IP Right Cessation
2007
- 2007-12-21 US US11/963,144 patent/US8309561B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN103784458A (zh)	2014-05-14
JPWO2005061466A1 (ja)	2007-12-13
EP2615087A2 (en)	2013-07-17
US20050222141A1 (en)	2005-10-06
CN1917881A (zh)	2007-02-21
US20080108634A1 (en)	2008-05-08
CA2550843A1 (en)	2005-07-07
AU2004303696A1 (en)	2005-07-07
RU2006126651A (ru)	2008-01-27
CN103784458B (zh)	2015-10-14
CA2550843C (en)	2013-04-02
US8309561B2 (en)	2012-11-13
IL176469A (en)	2012-12-31
EP1700850A1 (en)	2006-09-13
EP2803667A1 (en)	2014-11-19
JP4743659B2 (ja)	2011-08-10
WO2005061466A9 (ja)	2006-07-27
BRPI0418026A (pt)	2007-04-17
KR20110098980A (ko)	2011-09-02
EP1700850A4 (en)	2009-04-08
NO20063372L (no)	2006-09-20
KR20060127065A (ko)	2006-12-11
EP1700850B1 (en)	2015-07-15
KR101194176B1 (ko)	2012-10-24
US7345049B2 (en)	2008-03-18
ES2548853T3 (es)	2015-10-21
NO337628B1 (no)	2016-05-18
EP2615087A3 (en)	2013-08-07
WO2005061466A1 (ja)	2005-07-07
IL176469A0 (en)	2006-10-05
RU2390520C2 (ru)	2010-05-27
NZ548420A (en)	2010-03-26
AU2004303696B2 (en)	2011-03-31
CN1917881B (zh)	2014-11-26

Publication	Publication Date	Title
ZA200605587B (en)	2008-02-27	Novel phenylalanine derivative
EP1846035B1 (en)	2011-09-21	Combination therapy
RU2437885C2 (ru)	2011-12-27	Производные дигидропиразолопиримидинона
CA2717948C (en)	2016-09-06	5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
JP2002523502A5 (ru)	2006-10-05
WO2000012497B1 (en)	2000-09-08	Quinazoline derivatives as medicaments
CN102399220A (zh)	2012-04-04	三并环类PI3K和mTOR双重抑制剂
JP2022524456A (ja)	2022-05-02	Ｈｂｖ感染又はｈｂｖ誘導性疾患の治療における使用のための縮合環ピリミドン誘導体
AU2010295492B2 (en)	2016-05-05	Novel compounds and therapeutic use thereof for protein kinase inhibition
KR20010012995A (ko)	2001-02-26	발기부전 치료제
TW200407122A (en)	2004-05-16	Hemiasterlin derivatives and uses thereof
EP0620224B1 (en)	1998-07-15	Triazolopyridazine derivatives, their production and use
CN106478631B (zh)	2019-04-05	长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法
CN102153553A (zh)	2011-08-17	含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
KR100280240B1 (ko)	2001-02-01	호산구 주화성 억제제
CN103664734A (zh)	2014-03-26	杂环羟肟酸类化合物及其药用组合物和应用
JPH07242544A (ja)	1995-09-19	抗腫瘍剤
AU2004270304A1 (en)	2005-03-17	Guanidine derivatives
EP1054669B1 (en)	2003-07-16	Use of thiadiazolo[4,3-a]pyridine derivatives
CN110272419A (zh)	2019-09-24	二氢吡啶并酞嗪酮衍生物、其制备方法及应用
JPH09323932A (ja)	1997-12-16	エイズ治療剤又は予防剤
WO2023109892A1 (zh)	2023-06-22	一种抑制或降解brd9的化合物及其组合物和药学上的应用
MXPA06007284A (en)	2006-12-13	Novel phenylalanine derivative
JP2869993B2 (ja)	1999-03-10	ベンゾチエピノトリアゾロピリダジン誘導体
AU2012331125A1 (en)	2014-05-22	2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases